Antheia, a trailblazer in pharmaceutical ingredient manufacturing, has signed a second government-backed project agreement under the Defense Production Act (DPA) Title III Program. This $12 million award, spanning two years, comes from the Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium) and will fast-track the domestic biomanufacturing of essential pharmaceutical ingredients. The announcement underscores Antheia’s growing momentum following recent funding secured through the BioMaP-Consortium and private investments.

“This agreement further cements the role of biomanufacturing as the advanced manufacturing technology of the future that can secure, onshore, and transform vital supply chains that our society relies on,” said Dr. Christina Smolke, Antheia CEO and co-founder. “We are proud to receive a second project agreement from the BioMaP-Consortium and look forward to working with this team to achieve our shared vision for pharma in the U.S.”

Antheia’s biomanufacturing platform represents a pivotal shift in securing critical pharmaceutical ingredients for the U.S. market. Currently, the nation is heavily reliant on foreign suppliers, a dependency that leaves public health vulnerable to disruptions. The project agreement will enable Antheia to domestically produce a vital pharmaceutical ingredient, scaling it to commercial levels.

Transforming the Pharmaceutical Supply Chain with Biomanufacturing

Antheia’s innovation aligns with the BioMaP-Consortium’s mission to strengthen the U.S. pharmaceutical and vaccine supply chain. By integrating raw material suppliers, cutting-edge manufacturing technology developers, and fill-finish service providers, the consortium, supported by the Biomedical Advanced Research and Development Authority (BARDA), ensures preparedness for public health crises.

This latest award positions Antheia as a key player in transforming the industry. The company’s biomanufacturing process not only reduces dependency on foreign imports but also enhances national security, economic stability, and public health resilience.

Federal Backing with Strategic Vision

This project, fully funded by the Department of Health and Human Services (HHS) through its Administration for Strategic Preparedness and Response (ASPR) under the DPA Title III Program, exemplifies federal commitment to bolstering domestic pharmaceutical manufacturing. The award builds on Antheia’s 2024 milestones, including its inaugural commercial-scale delivery of thebaine to a top pharmaceutical customer.

Antheia’s collaboration with the BioMaP-Consortium highlights the transformative potential of biomanufacturing. As the U.S. reimagines its pharmaceutical supply chain, innovations like Antheia’s biomanufacturing platform could redefine the industry’s landscape, ensuring the availability of critical medicines when and where they’re needed most.